Search Results
Prognostic blood biomarkers in the pre-clinical stages of Alzheimer’s disease
Prognostic value of blood-based biomarkers in predicting progression to dementia from SCD/MCI
Pre-clinical trial underway locally to identify biomarker for Alzheimer's disease
2/12/2021: Disclosing Amyloid Biomarker Results in Preclinical Alzheimer's Disease
sGFAP: a potential diagnostic and prognostic marker in FTD
The ability of plasma P-tau231 to detect preclinical Alzheimer’s disease
A future scenario: digital and blood biomarkers for Alzheimer’s disease diagnosis in primary care
Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society
The need for improved prognostic markers in Alzheimer’s disease
How are blood-based biomarkers currently used in Alzheimer’s disease?
Use of AD blood-based biomarkers for trial enrolment
Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia
